Drug-Eluting Stents in Patients with Chronic Kidney Disease: A Prospective Registry Study

BACKGROUND: Chronic kidney disease (CKD) is strongly associated with adverse outcomes after percutaneous coronary intervention (PCI). There are limited data on the effectiveness of drug-eluting stents (DES) in patients with CKD. METHODOLOGY/PRINCIPAL FINDINGS: Of 3,752 consecutive patients enrolled in the Guthrie PCI Registry between 2001 and 2006, 436 patients with CKD - defined as a creatinine clearance <60 mL/min - were included in this study. Patients who received DES were compared to those who received bare metal stents (BMS). Patients were followed for a mean duration of 3 years after the index PCI to determine the prognostic impact of stent type. Study end-points were all-cause death, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST) and the composite of major adverse cardiovascular events (MACE), defined as death, MI or TVR. Patients receiving DES in our study, by virtue of physician selection, had more stable coronary artery disease and had lower baseline risk of thrombotic or restenotic events. Kaplan-Meier estimates of proportions of patients reaching the end-points were significantly lower for DES vs. BMS for all-cause death (p = 0.0008), TVR (p = 0.029) and MACE (p = 0.0015), but not MI (p = 0.945) or ST (p = 0.88). Multivariable analysis with propensity adjustment demonstrated that DES implantation was an independent predictor of lower rates of all-cause death (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.25-0.92), TVR (HR 0.50, 95% CI 0.27-0.94) and MACE (HR 0.62, 95% CI 0.41-0.94). CONCLUSIONS: In a contemporary PCI registry, selective use of DES in patients with CKD was safe and effective in the long term, with lower risk of all-cause death, TVR and MACE and similar risk of MI and ST as compared with BMS. The mortality benefit may be a result of selection bias and residual confounding, or represent a true finding; a hypothesis that warrants clarification by randomized clinical trials

Current OCT Approaches Do Not Reliably Identify TCFAs

It is now clearly established that Thin-Capped Fibroatheromas (TCFAs) lead to most Acute Coronary Syndromes (ACSs). The ability to selectively intervene on TCFAs predisposed to rupture and ACSs would dramatically alter the practice of cardiology. While the ability of OCT to identify thin walled plaques at micron scale resolutions has represented a major advance, it is a misconception that it can reliably identify TCFAs. One major reason is that the ‘diffuse border’ criteria currently used to determine ‘lipid plaque’ is almost undoubtedly from high scattering in the intima and not because of core composition (necrotic core). A second reason is that, rather than looking at lipid collections, studies need to be focused on identifying necrotic cores with OCT. Necrotic cores are characteristic of TCFAs and not lipid collections. Numerous other OCT approaches are available which can potentially accurately assess TCFAs, but these have not been aggressively pursed which we believe likely stems in part from the misconceptions over the efficacy of ‘diffuse borders’

Clinical Characteristics.

<p><i>p</i><0.05 for pairwise comparison between DES and BMS groups.</p><p>Continuous variables are expressed as mean ± standard deviation (median). Categorical variables are expressed counts (percentages).</p><p>BMS  =  bare metal stent; CABG  =  coronary artery bypass graft surgery; DES  =  drug-eluting stents; MI  =  myocardial infarction; NSTEMI  =  non-ST-segment elevation myocardial infarction; PCI  =  percutaneous coronary intervention; STEMI  =  ST-segment elevation myocardial infarction.</p

Study Patients.

<p>BMS  =  bare metal stent; Creatinine clearance  =  creatinine clearance; DES  =  drug-eluting stents; PCI  =  percutaneous coronary intervention.</p

Multivariable Analysis with Propensity Adjustment Denoting the Impact of Stent Type on All-Cause Death, TVR and MACE.

<p>BMS  =  bare metal stent; DES  =  drug-eluting stents; MACE  =  major adverse cardiovascular events; TVR  =  target vessel revascularization.</p